• E-mail :[email]
  • Phone : +33 4 76 54 94 76
  • Location : Grenoble, France
Last update 2011-04-04 10:18:03.53

Beatrice Eymin PhD Molecular and Cellular Biology, Pharmacy MD

Course and current status


2006. Habilitation à Diriger des Recherches, Molecular and Cellular Biology, Université Joseph Fourier, Grenoble

1999. Thesis in Molecular and Cellular Biology, Université de Dijon, France

1998. Diplôme d’Etudes Spécialisées (DES) de Pharmacie Spécialisée, Université de Pharmacie, Université de Bourgogne, Dijon 

1998. Thesis in Pharmacy, UFR de Pharmacie, Université de Bourgogne, Dijon

1995. Master M2 in Biochemistry, Cellular and Molecular Biology, Mention Bien (1/32), Université des Sciences, Université de Bourgogne, Dijon

1993. Diplôme d’Etat de Pharmacie, UFR de Pharmacie, Université Joseph Fourier, Grenoble



Actual position: CR1 INSERM. Principal investigator (PI) inside the team 2 « Molecular Basis of Lung Cancer Progression » of INSERM unit U823. Institut Albert Bonniot. Grenoble. France.

2006- Permanent position at INSERM (Chargée de Recherche CR1).

INSERM Unit U823, Team: Molecular Basis of Lung Cancer Progression,

Institut Albert Bonniot, Grenoble, France.

«Deregulation of p53/Rb signaling pathways in human lung carcinogenesis». 

2001-2005. Permanent position at INSERM (Chargée de Recherche CR2).

INSERM Unit U578, Groupe de Recherche sur le Cancer du Poumon, Institut Albert Bonniot. 

1998-2001. Post-doctoral position (Poste Accueil INSERM).

INSERM Unit U578, Groupe de Recherche sur le Cancer du Poumon, Institut Albert Bonniot.

1993-1998. Interne en Pharmacie Spécialisée. CHU de Dijon

1993-1996: Hematology - Dr GUY

1996-1997: Pharmacy - Dr DURNET

1997-1998: Clinical Hematology - Dr GUY

1995-1998. Doctoral position.

INSERM Unit U517. «Cell Death and Cancer». Pr Eric Solary. Facultés de Médecine et de Pharmacie, Université de Bourgogne, Dijon.

Title of the thesis : Relationships between cell cycle and chemotherapy-induced apoptosis in human leukemic cells. Implication of gadd153 and p27Kip1.


Lung cancer

pre mRNA alternative splicing


Cellular proliferation and Apoptosis

Transcription factors and SR proteins 

Cellular signaling pathways



Courses (4 hours) in Cellular Signaling Pathways (UE5331, Master M2 Integrative and Cellular Biology, University of Biology, Grenoble)

Jury of Master M2 « Integrative and Cellular Biology » 2007 and 2008

Member of jury of PhD 

Supervisor of 4 PhD students 

Supervisor of 3 Master M2 students


Member of the Specialist Commission of the department of Cellular Biology of the university of Biology of Grenoble (October 2007-2009)

Expert of Ligue Nationale Contre le Cancer (Comité Régional)

Scientific summary

Lung cancer is a major public health problem. Despite diagnosis and treatment improvements, ten-years overall lung cancer survival is less than 5%, claiming more deaths than colon, breast and prostate carcinoma all togethers. Twenty-five percents of patients only can benefit of an early diagnosis allowing surgical resection, with 60-80% survival at five years. In this setting, our main objectives are to identify some of the molecular biomarkers that could be predictive of tumor progression and response to therapies. Identification of such biomarkers should improve early detection of lung tumors, as well as should help in the establishment of new targeted therapies more efficient and less agressive.

In this setting, our research focused on different aspects:

- Identification of cellular signalling pathways involved in the control of lung tumor cells proliferation and/or apoptosis.

- Identification of target genes involved in lung tumor cell response to chemotherapeutic agents and targeted therapies such as anti-angiogenic therapies.

Image d’exemple